MAHWAH, N.J., November 17, 2025--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on innovative and ...

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and ...

Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and ...

KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

(RTTNews) - KORU Medical Systems, Inc. (KRMD) is planning to submit a 510(k) application to the FDA for its FreedomEDGE Syringe Infusion System in the fourth quarter of 2025 or in the first quarter of ...

A subcutaneous formulation of daratumumab exhibited similar pharmacokinetics as the standard IV formulation among patients with relapsed or refractory multiple myeloma, according to results from the ...

KORU Medical Systems to Present Promising Results on the Use of the FreedomEDGE® Syringe Infusion System in Infusion Centers at ESID/EHA/SIOPE Focused Symposium 2025 KORU Medical Systems, Inc. (NASDAQ ...